Oruka Therapeutics, Inc.
NASDAQORKA short interest surges 37% in one week to 18.8% of float, driven by heavy short accumulation as biotech faces competition headwinds.
ORKA enters July with one of the more charged setups in small-cap biotech: the stock has rallied 63% in a month, short sellers are quietly reducing exposure, and UBS just raised its price target — yet the borrow market…
Oruka Therapeutics enters its June 2 earnings event riding a contradictory setup: the stock is down 12% over the past month to $55.01, yet options traders have turned sharply more optimistic than at any point in recent…
Snapshot as of 17 Jul 2026
Oruka Therapeutics heads into its May 20 earnings call with one of the most aggressive short-interest buildups seen in the small-cap biotech space this year — and a Street that, for now, is pointing firmly in the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ORKA — free to start on ORTEX.
Sign up for free →Open ORKA on ORTEX